| Ren Delin | 01-Dec-23 | | ED | | |
| Xiong Wei | 01-Dec-23 | | CFO | | |
| Wu Yuting | 14-Nov-22 | | NED | | |
| Fu Lei | 14-Apr-19 | | INED | | |
| Li Cathy Xiangrong | 14-Apr-19 | | INED | | |
| Wang Haiguang | 14-Apr-19 | | INED | | |
| Chau Anita Hing Ling | 10-Jul-18 | | CoSec | | |
| Fei Xiaoyu | 10-Jul-18 | | CoSec | | |
| Mao Cheney Chen | 03-Jul-18 | | Ch, CEO | | |
| Wu Ying | 07-Sep-09 | | ED | | |
| Wang Stephen Hui | 18-Jan-24 | 16-Feb-26 | NED | | Mr. Wang resigned in order to devote more time to pursue his other personal and business engagements. |
| Wang Haiguang | | 27-Mar-25 | MbNC | | Mr. WANG Haiguang ceases to be a member of the nomination committee of the Board to enhance the corporate governance of the Company and to fulfill the new gender diversity requirement of the nomination committee under the amended CG Code and the Listing Rules. |
| Wang Zheren | 29-Apr-21 | 27-Sep-24 | CFO | | |
| Wang Zheren | | 27-Sep-24 | Co-Chief Financial Officer of the Group | | Mr. Wang has tendered his resignation from the role of Co-Chief Financial Officer to focus more on leading the financial management and strategic development of Viva Shanghai. |
| Ren Delin | 03-Jul-18 | 01-Dec-23 | Pres | | The change in executive responsibilities will enable Mr. Ren to focus more of his attention to leading the Group’s CRO and drug discovery businesses. |
| Sun Yanyan | 30-Mar-20 | 14-Nov-22 | NED | | To devote more time to pursue her other business engagements |
| Hua Fengmao | 29-Apr-21 | 30-Jun-21 | ED | | |
| Hua Fengmao | 03-Jul-18 | 29-Apr-21 | FD | | |
| Mao Jun | 03-Jul-18 | 03-Nov-20 | Co-Fdr, NED | | |
| Wu John Jiong | 03-Jul-18 | 30-Mar-20 | NED | | |
